About This Report

Over the past 6 years, three major events have impacted the autism spectrum disorders industry . In 2006, Risperdal became the first drug to receive approval from the US FDA for the symptomatic treatment of irritability in children and adolescents with ASDs. Later, in 2009, the FDA approval Abilify for the same indication. In 2008, generic risperidone launched following Risperdal’s US patent expiry.

What's Included in This Report?


* Overview of industry ed and pipeline drugs in clinical development for autism spectrum disorders.

* Analysis of the industry positioning of each product approved for the treatment of autism spectrum disorders.

* Assessment of the strengths, weaknesses, opportunities and threats for industry ed and late-stage pipeline candidates.

* Summary of the clinical and commercial attractiveness for each of the industry ed products.

* Insight from key opinion leaders on industry ed and pipeline products.

Key Market Facts

Risperdal and Abilify are the only two products approved for the treatment of autism spectrum disorders (ASDs). Both of these atypical antipsychotics are indicated for the management of irritability symptoms associated with ASDs in the US. Due to the failure of these drugs to address the core symptoms of ASDs, many other drugs are used off-label.
Abilify is the most recent entrant to the ASDs industry, having received US Food and Drug Administration (FDA) approval in November 2009. The drug's partial agonism of dopamine receptors unique mechanism of action is considered a key differentiating factor, producing a superior side-effect profile compared to other atypical antipsychotics.
To date, none of the four late-stage pipeline candidates for autism spectrum disorders has publically presented the late-stage Phase II or III trial data necessary for the clinical assessment of these compounds.

Why Should You Buy This Report?


* What are the key differentiating features of approved therapies for the treatment of autism spectrum disorders?

* How do key opinion leaders perceive available treatments for autism spectrum disorders?

* What opportunities are there for existing players in the autism spectrum disorders industry to increase their industry share?

* What is the development status of current pipeline candidates development status?

* What clinical trial design are current pipeline canddiates following? What do pipeline candidates need to demonstrate in order to be successful?

Table Of Contents

Summary
Strategic scoping and focus
Datamonitor key findings
Related reports
OVERVIEW
Catalyst
Summary
MARKET DEFINITION AND OVERVIEW
Industry definition
Product overview
MARKETED PRODUCT PROFILES
Abilify (aripiprazole; Bristol-Myers Squibb/Otsuka Pharmaceuticals)
Drug presentation
Drug pipeline analysis
SWOT analysis
Portfolio
Clinical and commercial attractiveness
Risperdal (risperidone; Johnson and Johnson)
Drug presentation
Drug pipeline analysis
SWOT analysis
Portfolio
Clinical and commercial attractiveness
PIPELINE PRODUCT PROFILES
CM-AT (Curemark)
Drug presentation
Drug pipeline analysis
SWOT analysis
Other drugs in clinical development for autism spectrum disorders
STX-209 (arbaclofen; Seaside Therapeutics)
UCB-MNC (umbilical cord blood mononuclear stem cells; Beike Biotech)
CYP-2001 (carbetocin; Cypress Bioscience)
BIBLIOGRAPHY
Journal papers
Websites
Datamonitor reports
APPENDIX
Contributing experts
Conferences attended
Report methodology

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Parkinson's Disease - Global Drug Forecast and Market Analysis to 2022

PharmaPoint: Parkinson's Disease - Global Drug Forecast and Market Analysis to 2022

  • $ 9 995
  • Industry report
  • March 2014
  • by Global Data

PharmaPoint: Parkinson's Disease - Global Drug Forecast and Market Analysis to 2022 Summary Parkinson's disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, ...

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

  • $ 9 995
  • Industry report
  • April 2014
  • by Global Data

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most ...

Analytical Tool - Hematological Cancers

Analytical Tool - Hematological Cancers

  • $ 8 925
  • Industry report
  • March 2014
  • by Bioseeker

"Analytical Tool - Hematological Cancers" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in R&D and business development in hematological cancers. It is ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.